Clinical interpretation of *KCNH2* variants using a robust PS3/BS3 functional patch clamp assay

Kate L. Thomson,[1] Connie Jiang,[2,3] Ebony Richardson,[4,5] Dominik S. Westphal,[6,7,8] Tobias Burkard,[9] Cordula M. Wolf,[8,9,10] Matteo Vatta,[11] Steven M. Harrison,[12] Jodie Ingles,[4,5] Connie R. Bezzina,[8,13] Brett M. Kroncke,[14] Jamie I. Vandenberg,[3,15,*] and Chai-Ann Ng[3,15,**]

[1]Oxford Genetics Laboratories, Churchill Hospital, Oxford, UK. [2]Faculty of Medicine and Health, UNSW Sydney, Kensington, NSW, Australia. [3]Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW, Australia. [4]Centre for Population Genomics, Garvan Institute of Medical Research and UNSW Sydney, Sydney, Australia. [5]Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. [6]Institute of Human Genetics, Klinikum rechts der Isar, School of Medicine and Health, Technical University of Munich, Munich, Germany. [7]Department of Internal Medicine I, Klinikum Rechts der Isar, School of Medicine and Health, Technical University of Munich, Germany. [8]European Reference Network for Rare, Low Prevalence and Complex Diseases of the Heart: ERN GUARD-Heart. [9]Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, Technical University of Munich, School of Medicine and Health, Munich, Germany. [10]DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany. [11]Invitae Corporation, San Francisco, CA, USA. [12]Ambry Genetics, Aliso Viejo, CA, USA. [13]Department of Experimental Cardiology, Amsterdam Cardiovascular Sciences, University of Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands. [14]Vanderbilt Center for Arrhythmia Research and Therapeutics, Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. [15]School of Clinical Medicine, UNSW Sydney, Darlinghurst, NSW, Australia.

Correspondence should be addressed to

*Jamie I. Vandenberg MBBS, Ph.D, Victor Chang Cardiac Research Institute, 405 Liverpool St, Darlinghurst, NSW 2010, Australia. E-mail: j.vandenberg@victorchang.edu.au; Tel: +61 2 9295 8687 and

**Chai-Ann Ng, Ph.D., Victor Chang Cardiac Research Institute, 405 Liverpool St, Darlinghurst, NSW 2010, Australia. E-mail: c.ng@victorchang.edu.au; Tel: +61 2 9295 8687

Summary

Long QT syndrome (LQTS), caused by the dysfunction of cardiac ion channels, increases the risk of sudden death in otherwise healthy young people. For many variants in LQTS genes there is insufficient evidence to make a definitive genetic diagnosis. We have established a robust functional patch clamp assay to facilitate classification of missense variants in *KCNH2*, one of the key LQTS genes. A curated set of 30 benign and 30 pathogenic missense variants were used to establish the range of normal and abnormal function. The extent to which variants reduced protein function was quantified using Z-scores; the number of standard deviations from the mean of the normalised current density of the set of benign variant controls. A Z-score of –2 defined the threshold for abnormal loss-of-function, which corresponds to 55% wild-type function. More extreme Z-scores were observed for variants with a greater loss-of-function effect. We propose that the Z-score for each variant can be used to inform the application and weighting of abnormal and normal functional evidence criteria (PS3 and BS3) within the American College of Medical Genetics and Genomics (ACMG) variant classification framework. The validity of this approach was demonstrated using a series of 18 *KCNH2* missense variants detected in a childhood onset LQTS cohort, where the level of function assessed using our assay correlated to the Schwartz score (a scoring system

50 used to quantify the probability of a clinical diagnosis of LQTS[1]) and the length of the QTc
51 interval.
52
53 Long QT syndrome (LQTS; MIM:192500) is a rare genetic disorder caused by variants
54 in genes which encode cardiac ion channel proteins. Abnormal variants in these genes lead
55 to cardiac ion channel dysfunction, which can result in cardiac arrhythmia and an increased
56 risk of sudden death, often with no prior symptoms. Genetic testing is recognised as a key
57 component of patient management and is recommended by clinical guidelines.[2] Establishing
58 a genetic diagnosis can inform clinical management and treatment strategies, provide greater
59 accuracy in assessing prognosis, and enable reproductive counselling. Importantly, as not all
60 individuals with a pathogenic variant present with clinical signs or symptoms of LQTS, where
61 a genetic diagnosis is confirmed in an affected individual, genetic testing can be offered to
62 family members, to identify those at risk. The perceived clinical importance of making a
63 presymptomatic genetic diagnosis of LQTS is highlighted by the inclusion of the key causal
64 genes in the ACMG list for reporting of secondary findings in clinical exome and genome
65 sequencing.[3]
66
67 Current genome sequencing technologies enable more comprehensive genetic
68 analysis to be performed cost effectively and genetic testing has become more widely
69 adopted for LQTS. While this has led to an increase in the proportion of patients with a genetic
70 diagnosis, the interpretation of genetic test results remains challenging. Due to lack of
71 definitive evidence for pathogenicity, many missense variants detected in LQTS genes are
72 classified as variants of uncertain clinical significance (VUS), which are not actionable
73 clinically. High numbers of VUS can reduce the clinical utility of genetic testing.

74

75 In a recent study,[4] we demonstrated the utility of a high throughput patch-clamp assay
76 to assess the functional consequences of a set of 31 missense variants in the *KCNH2* gene
77 (Table 1). [4,5] This gene encodes Kv11.1, a protein component of the voltage-gated potassium
78 ion channel, which is responsible for the rapid delayed rectifier current (I_{Kr}). Loss-of-function
79 variants in this gene are one of the most common causes of LQTS.[5] This assay, which
80 quantifies the current density at –50mV as a surrogate for I_{Kr} current in heart cells, was able
81 to clearly discriminate between missense variants with normal and abnormal loss-of-function
82 (LoF).[4]

83

84 We previously illustrated how data from this assay could be used to inform clinical
85 variant classification using the American College of Medical Genetics and the Association for
86 Molecular Pathology (ACMG/AMP) framework, providing statistical support for application
87 of the functional evidence (PS3 and BS3 criteria) with 'supporting' or 'moderate' weighting.[4]
88 In this study, we expand on our previous work,[4] undertaking functional analysis of additional
89 variants to give a total of 30 pathogenic and 30 benign variant controls (Table 1). The 30
90 benign / likely benign variant controls were selected on the basis of their minor allele
91 frequency (MAF) in the Genome Aggregation database (gnomAD;maximum population
92 filtering allele frequency[6] [PopMax FAF] greater than $5x10^{-5}$, see supplementary materials).
93 The advantage of using a larger number of benign variant controls, selected based on the
94 MAF, is that we were able to sample a broader range of biological and experimental variation,
95 and more clearly define a range for normal function measured by patch clamp
96 electrophysiology (Figure 1 and Figure S2). Using our assay, the functionally normal range was
97 defined by a Z-score within ±2 of the mean normalised current density determined from 30

98 benign control variants. The functionally abnormal LoF range was defined by a Z-score of –2
99 or below, corresponding to a variant having less than 55% of normal function, a clinically
100 relevant threshold consistent with protein haploinsufficiency.[7]
101
102 In our previous study, the 17 pathogenic variant controls had various levels of reduced
103 function. In this study, we included an additional 13 pathogenic variant controls (Table 1 and
104 Table S1) to increase the statistical power of the assay (Table 2). The experimental procedure
105 is described in the supplementary materials. Four out of the 30 pathogenic variant controls
106 were observed in gnomAD, however, with the exception of the Finnish founder variant,
107 p.(Leu552Ser),[7,8] all had a minor filtering allele frequency lower than the threshold selected
108 for benign control variants (Table S1). All 30 pathogenic variant controls had Z-scores of –2 or
109 less (Figure 1 and Table S3). Assay performance was evaluated using the approach
110 recommended by the Clinical Genome Resource (ClinGen) Sequence Variant Interpretation
111 (SVI) Working Group[9]; the odds of pathogenicity (OddsPath) were determined to be 30 for
112 abnormal function (PS3) and 0.034 for normal BS3 function (Table 2).
113
114 To integrate this functional data into variant classification, and to take into consideration
115 the various levels of reduced function revealed by this assay, we considered a graded
116 evidence scale weighted according to the severity of the LoF determined by the Z-score. Using
117 this scale, variants with Z-score between –2 and –3 (mild LoF), –3 and –4 (moderate LoF) and
118 less than –4 (severe LoF) could be categorised as PS3_supporting, PS3_moderate or
119 PS3_strong, respectively. It is important to note that this *in vitro* cell model system may not
120 fully reflect protein function *in vivo* and might not capture all abnormal LoF. Taking into
121 consideration these limitations, we proposed that normal function variants with a Z-score

122 between 0 and 1 or –1 could be classified as BS3_moderate and Z-score between 1 and 2 or
123 –1 and –2 as BS3_supporting (Figure 1).
124
125 To investigate the utility of our approach, the functional evidence level determined from
126 this assay was applied to enhance the classification of 18 *KCNH2* missense variants detected
127 by Westphal *et al* in children with suspected LQTS.[10] Evidence of abnormal LoF was found for
128 14 missense variants (Figure 2A, yellow and brown circles and Table S3). Four variants were
129 in the range of normal function (Table S3). Two of these variants (p.Asp259Asn and
130 p.Thr983Ile), were detected in children who had been included in the cohort due to a family
131 history sudden cardiac death, but had normal QTc and a Schwartz score of less than 1 (low
132 probability of LQTS[1]) (Figure 2C). The p.Val409Ile variant was found in a child with a Schwartz
133 score of 2 (intermediate probability of LQTS[1]). The p.Pro393Leu variant was found in a child
134 who was also heterozygous for the p.Arg176Trp variant, a possible risk allele,[11] which has
135 been described as a founder variant in the Finnish population.[12]
136
137 Considering data from 32 paediatric LQTS cases in this cohort who were heterozygous for
138 one of these *KCNH2* missense variants, there was a negative correlation between the Z-score
139 determined by this assay and Schwartz score (r = –0.74 (Figure 2B) with a R2 of 0.54 from
140 linear regression). Overall, the variants that were determined by our assay to have severe LoF
141 were detected in individuals with a more severe clinical phenotype (measured by Schwartz
142 score) and a more prolonged QTc, this is consistent with previous observations.[13,14] The
143 variant classifications in Westphal *et al*[10] were revised by applying the level of functional
144 evidence at the strength determined by the Z-scores (Table S3). Considering this additional

145 evidence, the classification of one variant (p.Leu697His) was upgraded from VUS to likely
146 pathogenic after PS3 was applied at strong level (Table S2).
147
148 Overall, the findings of our study indicate that the functional evidence produced by this
149 validated assay is extremely valuable for the interpretation of *KCNH2* missense variants in the
150 context of LQTS. However, functional data from this assay should not be used as sole evidence
151 to classify a variant as pathogenic or benign, but should be considered in the context of other
152 evidence, as outlined in the ACMG/AMP framework.[15]
153
154 At present, we have not extensively examined the functional range of so-called risk
155 alleles, which display incomplete penetrance and may only have pathogenic potential in the
156 presence of other environmental or genetic risk factors. For example, the p.(Arg176Trp)
157 variant, which was detected in the Westphal *et al* childhood onset LQTS cohort, has been
158 reported as founder variant in the Finnish population[8] and reported to be enriched in
159 individuals referred for LQTS genetic testing but lacking a molecular diagnosis.[16] The
160 frequency of this variant in the gnomAD European (non-Finnish) population was higher than
161 the threshold used to select benign variant controls for this study, however, it was
162 determined by the assay to have a mild LoF effect (Z-score –2.75); these findings are
163 consistent with this being a variant with low or incomplete penetrance. Further studies may
164 provide additional functional evidence which might help clarify the pathogenic potential of
165 this class of variant.
166
167 In conclusion, this patch clamp assay, which used extensively characterised variant
168 controls to calibrate thresholds for normal and abnormal loss-of-function missense variants

169 in the *KCNH2* gene, provides reliable functional evidence that can be incorporated into clinical
170 variant classification. This has potential to reduce uncertainty in variant interpretation in this
171 clinically important gene.
172
173 **Data and code availability**
174 The current traces from the patch clamp electrophysiology that support the findings of this
175 study are available as csv files upon request. The corresponding analysis scripts for patch-
176 clamp experiments are available at https://git.victorchang.
177 edu.au/projects/SADA/repos/syncropatch_automated_analysis/browse.
178
179 **Supplemental information**
180 Table S1– Summary of *KCNH2* benign and pathogenic variant controls.
181 Table S2 – Summary of *KCNH2* variants reclassification after functional assessment.
182 Table S3 – Summary of Z-score and patch clamp data for all variants.
183 Table S4 – Summary of maximum credible population allele frequency.
184
185 **Acknowledgements**
186 This work was funded by an NSW Cardiovascular Disease Senior Scientist grant (J.I.V.), an
187 National Health and Medical Research Council Principal Research Fellowship (J.I.V.), MRFF
188 Genomics Health Futures Mission grant (J.I.V. and C.A.N). We also acknowledge support
189 from the Victor Chang Cardiac Research Institute Innovation Centre, funded by the NSW
190 Government.
191
192 **Author contributions**

Conceptualization: K.L.T., J.I.V., C.A.N.; Data curation: K.L.T., E.R., C.A.N.; Formal Analysis: K.L.T., C.J., E.R., D.S.W., T.B., C.M.W., M.V., S.M.H., J.I.V., C.A.N.; Funding acquisition: J.I.V.; Methodology: K.L.T., C.J., E.R., J.I., J.I.V., C.A.N.; Writing – original draft: K.L.T., J.I.V., C.A.N.; Writing – review & editing: K.L.T., E.R., D.S.W., T.B., C.M.W., M.V., S.M.H., J.I., C.R.B., B.M.K., J.I.V., C.A.N.

Declaration of interests

M.V. is an employee and stockholder of Invitae Corporation. The other authors declare no competing interests.

Figure Legend

Figure 1: Establishment of graded functional evidence strength based on the Z-score determined from benign and pathogenic variant controls. (A) The cut-off for functionally normal (blue circles) and abnormal (brown circles) was determined to be 55% of WT using 2 standard deviations below the mean of all benign controls. (B) The establishment of evidence strength for functional data based on the Z-score of –2 by using 30 benign variant controls. The level of evidence strength was graded based on the Z-score where normal function for BS3 at moderate (between 0 and ± 1) or supporting (between 1 and 2 or –1 and –2). The abnormal function for PS3 at supporting (between –2 to –3), moderate (between –3 to –4) and strong (less than –4). The comparison of benign variant controls was made against known benign / likely benign variants classified by two other diagnostic laboratories. All the 30 pathogenic variant controls used were found to have function less than the benign variant controls (see Table S3).

Figure 2: Missense *KCNH2* variants from children with long QT syndrome. (A) The functional assessment of these variants using patch-clamp assay. Blue region indicates the functionally normal

range determined from a set of 30 benign variant controls. Variants are colour-coded to indicate the Z-score: blue for Z-score between 0 and ±1, light blue for Z-score between 1 and 2 or –1 and –2, yellow for Z-score between –2 to –3, orange for Z-score between –3 to –4 and brown for Z-score less than –4. Variants that were downgraded to VUS in Westphal *et al*[10] are indicated by #. The heterozygous variant p.(Pro393Leu) with a risk allele p.(Arg176Trp) is indicated by red outline. (B) The correlation of Schwartz score from children that have these variants and the corresponding function of the variant assessed by patch clamp assay. Region of Schwartz score above 3.5 is highlighted to indicate the severity of the LQT clinical phenotype. The Pearson r for this correlation is –0.74 and the R^2 of linear regression is 0.54 with p=0.0007. The Schwartz score for the compound heterozygous p.(Pro393Leu) with a risk allele p.(Arg176Trp) was not included. Data is presented as mean +/- s.e.m. (C) The correlation of QTc and the corresponding function of the variant assessed by patch clamp assay. Region of QTc above 480ms is highlighted. The Pearson r for this correlation is –0.76 and the R^2 of linear regression is 0.58 with p=0.0004. The QTc for the compound heterozygous p.(Pro393Leu) with a risk allele p.(Arg176Trp) was not included. Data is presented as mean +/- s.e.m.

Table 1: Summary of the 60 variant controls.

Benign/Likely Benign		
This study	17	Total of 30
Jiang *et al* 2022	13	
Pathogenic/Likely pathogenic		
This study	13	Total of 30
Jiang *et al* 2022	17	

The details for each of the variant controls are available in Table S1.

Table 2: Odds of Pathogenicity (OddsPath).

# Classified			Proportion pathogenic (Prior, P_1)	Assay result				"+1 proportions" (Posterior, P_2)		OddsPath=[P_2 x (1- P_1)] / [(1- P_2) x P_1]	
Total	Pathogenic	Benign		Total assay Abnormal	Total assay Normal	True Path in Abnormal	True Path in Normal	Proportion Path in Abnormal	Proportion Path in Normal	Pathogenic (Evidence strength equivalent)	Benign (Evidence strength equivalent)
60	30	30	0.50	31	29	30	0	0.97	0.03	30.0 (PS3_Strong)	0.034 (BS3_Strong)

Modified from Fayer *et al* 2021.[17] Note: this estimate "adds 1.0" to the numerator and denominator to do a calculation.

References

1. Schwartz, P.J., and Crotti, L. (2011). QTc behavior during exercise and genetic testing for the long-QT syndrome. Circulation *124*, 2181-2184. 10.1161/CIRCULATIONAHA.111.062182.
2. Wilde, A.A.M., Semsarian, C., Marquez, M.F., Shamloo, A.S., Ackerman, M.J., Ashley, E.A., Sternick, E.B., Barajas-Martinez, H., Behr, E.R., Bezzina, C.R., et al. (2022). European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace *24*, 1307-1367. 10.1093/europace/euac030.
3. Miller, D.T., Lee, K., Abul-Husn, N.S., Amendola, L.M., Brothers, K., Chung, W.K., Gollob, M.H., Gordon, A.S., Harrison, S.M., Hershberger, R.E., et al. (2022). ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med *24*, 1407-1414. 10.1016/j.gim.2022.04.006.
4. Jiang, C., Richardson, E., Farr, J., Hill, A.P., Ullah, R., Kroncke, B.M., Harrison, S.M., Thomson, K.L., Ingles, J., Vandenberg, J.I., and Ng, C.A. (2022). A calibrated functional patch-clamp assay to enhance clinical variant interpretation in KCNH2-related long QT syndrome. Am. J. Hum. Genet. *109*, 1199-1207.
5. Adler, A., Novelli, V., Amin, A.S., Abiusi, E., Care, M., Nannenberg, E.A., Feilotter, H., Amenta, S., Mazza, D., Bikker, H., et al. (2020). An International, Multicentered, Evidence-Based Reappraisal of Genes Reported to Cause Congenital Long QT Syndrome. Circulation *141*, 418-428. 10.1161/CIRCULATIONAHA.119.043132.
6. Whiffin, N., Minikel, E., Walsh, R., O'Donnell-Luria, A.H., Karczewski, K., Ing, A.Y., Barton, P.J.R., Funke, B., Cook, S.A., MacArthur, D., and Ware, J.S. (2017).

Using high-resolution variant frequencies to empower clinical genome interpretation. Genet Med *19*, 1151-1158. 10.1038/gim.2017.26.

7. Piippo, K., Laitinen, P., Swan, H., Toivonen, L., Viitasalo, M., Pasternack, M., Paavonen, K., Chapman, H., Wann, K.T., Hirvela, E., et al. (2000). Homozygosity for a HERG potassium channel mutation causes a severe form of long QT syndrome: identification of an apparent founder mutation in the Finns. J. Am. Coll. Cardiol. *35*, 1919-1925. 10.1016/s0735-1097(00)00636-7.

8. Fodstad, H., Swan, H., Laitinen, P., Piippo, K., Paavonen, K., Viitasalo, M., Toivonen, L., and Kontula, K. (2004). Four potassium channel mutations account for 73% of the genetic spectrum underlying long-QT syndrome (LQTS) and provide evidence for a strong founder effect in Finland. Ann. Med. *36 Suppl 1*, 53-63. 10.1080/17431380410032689.

9. Brnich, S.E., Abou Tayoun, A.N., Couch, F.J., Cutting, G.R., Greenblatt, M.S., Heinen, C.D., Kanavy, D.M., Luo, X., McNulty, S.M., Starita, L.M., et al. (2020). Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome Med *12*, 3. 10.1186/s13073-019-0690-2.

10. Westphal, D.S., Burkard, T., Moscu-Gregor, A., Gebauer, R., Hessling, G., and Wolf, C.M. (2020). Reclassification of genetic variants in children with long QT syndrome. Mol Genet Genomic Med *8*, e1300. 10.1002/mgg3.1300.

11. Giudicessi, J.R., Roden, D.M., Wilde, A.A.M., and Ackerman, M.J. (2018). Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing. Circulation *137*, 619-630. 10.1161/CIRCULATIONAHA.117.030142.

12. Marjamaa, A., Salomaa, V., Newton-Cheh, C., Porthan, K., Reunanen, A., Karanko, H., Jula, A., Lahermo, P., Vaananen, H., Toivonen, L., et al. (2009). High prevalence of four long QT syndrome founder mutations in the Finnish population. Ann. Med. *41*, 234-240. 10.1080/07853890802668530.

13. Aizawa, T., Wada, Y., Hasegawa, K., Huang, H., Imamura, T., Gao, J., Kashiwa, A., Kohjitani, H., Fukuyama, M., Kato, K., et al. (2023). Non-missense variants of KCNH2 show better outcomes in type 2 long QT syndrome. Europace *25*, 1491-1499. 10.1093/europace/euac269.

14. Moss, A.J., Zareba, W., Kaufman, E.S., Gartman, E., Peterson, D.R., Benhorin, J., Towbin, J.A., Keating, M.T., Priori, S.G., Schwartz, P.J., et al. (2002). Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation *105*, 794-799.

15. Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, E., Spector, E., et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med *17*, 405-424. 10.1038/gim.2015.30.

16. Vatta, M., Truty, R., Garcia, J., Callis, T.E., Hatchell, K., Rojahn, S., Morales, A., Aradhya, S., and Nussbaum, R. (2021). Common Variants in KCNE1, KCNH2, and SCN5A May Impact Cardiac Arrhythmia Risk. Circ Genom Precis Med *14*, e003206. 10.1161/CIRCGEN.120.003206.

17. Fayer, S., Horton, C., Dines, J.N., Rubin, A.F., Richardson, M.E., McGoldrick, K., Hernandez, F., Pesaran, T., Karam, R., Shirts, B.H., et al. (2021). Closing the gap: Systematic integration of multiplexed functional data resolves variants of uncertain

significance in BRCA1, TP53, and PTEN. Am. J. Hum. Genet. 10.1016/j.ajhg.2021.11.001.

Figure 1


A
Normalised current density (sqrt)
(mean ±95% CI)
0.0
0.5
1.0
1.5
% WT
0
6
28
55
92
138
225
p.Lys897Thr
p.Pro347Ser
p.Arg885Cys
p.Ala233Ser
p.Glu978Lys
p.Lys93Arg
p.Ser981Gly
p.Arg181Gln
p.Asp144Val
p.Leu1045Phe
p.Val491Ile
p.Arg328Cys
p.Ala913Val
p.Val1038Met
p.Arg148Trp
p.Gly657Ser
p.Gly584Ser
p.Arg582Cys
p.Glu58Lys
p.Asp837Asn
p.Arg752Trp
p.Arg823Trp
p.Val822Met
p.Ser818Leu
p.Gly628Ser
p.Asp609Asn
p.Thr613Met
p.Ala561Thr
p.Tyr616Cys
p.Asn629Thr
neg ctrl
p.Pro967Leu
p.Gly873Ser
p.Pro141Leu
p.Gly236Val
p.Arg892Cys
p.Asp119His
p.Arg1047Leu
p.Thr1146Ser
p.Thr983Ile
p.Ala190Thr
p.Arg791Trp
p.Gly1036Asp
p.Pro910Leu
p.Gly903Arg
p.Ala448Ser
p.Asn629Ser
p.Arg531Trp
p.Ser660Leu
p.Leu552Ser
p.Asp774Tyr
p.Gly601Ser
p.His562Arg
p.Phe431Leu
p.Asn633Ser
p.Gly572Ser
p.Ala614Val
p.Ser641Phe
p.Ala561Val
p.Pro632Ser
p.Gly604Ser
B
Normalised current density (sqrt)
0.0
0.5
1.0
1.5
PS3
BS3
strong
moderate
supporting
supp
mod
supp
30 Benign controls
21 Invitae B / LB
23 Ambry B / LB
30 Pathogenic controls
Z-score
-8
-6
-4
-2
0
2
4

Figure 2


A
Normalised current density (sqrt)
(mean ± 95% CI)
Z-score
1.5
1.0
0.5
0.0
4
2
0
-2
-4
-6
-8
p.Asp259Asn:WT
p.Pro393Leu:WT
p.Thr983Ile:WT
p.Val409Leu:WT
p.Arg863Gln:WT
p.Asn629Ser:WT
p.Arg176Trp:WT
p.Arg681Trp:WT
p.Gly601Ser:WT
p.Leu697His:WT
p.Asp501Asn:WT
p.Pro334Leu:WT
p.Tyr611His:WT
p.Ile31Asn:WT
p.Gly572Ser:WT
p.Tyr616Asn:WT
p.Ala561Thr:WT
p.Ala561Val:WT
negative ctrl
B
Z-score
-8
-6
-4
-2
0
2
4
Schwartz score
7.0
3.5
0.0
0.0
0.5
1.0
1.5
Normalized current (sqrt)
C
Z-score
-8
-6
-4
-2
0
2
4
QTc (ms)
700
600
500
400
0.0
0.5
1.0
1.5
Normalized current (sqrt)